ANNEXON, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
ANNEXON, INC. (ANNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.33% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-12
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-06-30 was 4.33%, a 4.34% increase year-over-year.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 3.96%, a 11.80% decline year-over-year.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-06-30 was 4.15%, a 10.75% decline year-over-year.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.49%, a 3.70% increase year-over-year.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.49%, a 3.44% decline from fiscal 2024.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.65%, a 4.12% decline from fiscal 2023.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.85%, a 15.75% increase from fiscal 2022.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.19%, a 219.85% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.33% 10-Q · filed 2026-08-12 | 4.33% 10-Q · filed 2026-08-12 | ||
| 2026-03-31 | 3.96% 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 4.49% 10-K · filed 2026-03-30 | |||
| 2025-09-30 | 4.49% 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | 4.15% 10-Q · filed 2026-08-12 | 4.49% 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | 4.49% 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 4.65% 10-K · filed 2026-03-30 | |||
| 2024-09-30 | 4.15% 10-Q · filed 2025-11-10 | 4.65% 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | 4.65% 10-Q · filed 2025-08-14 | 4.65% 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | 4.33% 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | 4.85% 10-K · filed 2025-03-03 | |||
| 2023-09-30 | 4.42% 10-Q · filed 2024-11-14 | 4.42% 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | 3.86% 10-Q · filed 2024-08-12 | 4.02% 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | 4.02% 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | 4.19% 10-K · filed 2024-03-26 | |||
| 2022-09-30 | 3.61% 10-Q · filed 2023-11-13 | 3.61% 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | 3.37% 10-Q · filed 2023-08-07 | 3.37% 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | 2.11% 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | 1.31% 10-K · filed 2023-03-06 | |||
| 2021-09-30 | 1.10% 10-Q · filed 2022-11-03 | 1.10% 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | 1.01% 10-Q · filed 2022-08-08 | 1.02% 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | 1.02% 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | 1.45% 10-K · filed 2022-03-01 | |||
| 2020-09-30 | 0.38% 10-Q · filed 2021-11-09 | 1.45% 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | 0.45% 10-Q · filed 2021-08-16 | 1.45% 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | 1.45% 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | 2.61% 10-K · filed 2021-03-25 | |||
| 2019-09-30 | 2.61% 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | 2.20% 10-Q · filed 2020-09-08 | 2.61% 10-Q · filed 2020-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |